DexCom, Inc. (NASDAQ:DXCM) EVP Sells $75,317.11 in Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown sold 659 shares of the stock in a transaction on Friday, June 28th. The stock was sold at an average price of $114.29, for a total value of $75,317.11. Following the completion of the sale, the executive vice president now owns 66,901 shares in the company, valued at approximately $7,646,115.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Michael Jon Brown also recently made the following trade(s):

• On Friday, May 31st, Michael Jon Brown sold 652 shares of DexCom stock. The shares were sold at an average price of $119.24, for a total value of $77,744.48.
• On Tuesday, April 30th, Michael Jon Brown sold 629 shares of DexCom stock. The stock was sold at an average price of $126.25, for a total transaction of $79,411.25.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $113.38 on Monday. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. The company has a market cap of $45.09 billion, a price-to-earnings ratio of 73.15, a price-to-earnings-growth ratio of 2.77 and a beta of 1.22. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The company has a 50-day moving average price of $123.14 and a 200-day moving average price of $125.73.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. The business had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. As a group, equities analysts anticipate that DexCom, Inc. will post 1.78 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on DXCM shares. Raymond James boosted their price target on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 26th. Canaccord Genuity Group increased their target price on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, April 26th. UBS Group upped their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Royal Bank of Canada started coverage on DexCom in a report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective on the stock. Finally, StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $140.33.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Cary Street Partners Investment Advisory LLC increased its position in shares of DexCom by 11.1% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock valued at $108,000 after buying an additional 115 shares during the period. CX Institutional purchased a new position in shares of DexCom during the 4th quarter worth approximately $286,000. Bank of New Hampshire bought a new position in shares of DexCom in the 1st quarter worth approximately $1,508,000. abrdn plc lifted its stake in shares of DexCom by 21.1% in the 4th quarter. abrdn plc now owns 380,535 shares of the medical device company’s stock valued at $47,221,000 after purchasing an additional 66,348 shares during the period. Finally, Cerity Partners LLC boosted its position in shares of DexCom by 5,791.0% during the fourth quarter. Cerity Partners LLC now owns 463,973 shares of the medical device company’s stock valued at $57,574,000 after purchasing an additional 456,097 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.